Lactobacillus plantarum N-1 for preventing and/or improving benign prostatic hyperplasia
Patents no.: CN112402465A
Benign Prostatic Hyperplasia (BPH) is one of the most common urinary system diseases in middle-aged and elderly men, and causes bladder outlet obstruction due to Benign Hyperplasia of epithelium and stroma in the prostate transition region, thus causing a series of Benign diseases of lower urinary tract symptoms in patients. With the increasing aging degree of the global population, the incidence rate is increasing, the incidence rate of 50-year-old men reaches 42 percent, and the incidence rate of 80-year-old men reaches 80 percent. Currently, drug therapy and surgical treatment are the "cornerstones" of BPH treatment. However, the treatment effect of the existing medicines is not satisfactory yet, and the long-term curative effect is limited, such as: alpha-adrenergic blockers only partially ameliorate lower urinary tract symptoms and do not reduce prostate volume and reduce the risk of disease progression; although 5 α reductase inhibitors can reduce prostate volume, they are slow acting and respond poorly to these drugs in more than 30% of patients. In the uk, the cost for BPH treatment is estimated to exceed 1.8 billion pounds per year; also, the cost of treatment of BPH is increasing year by year in the united states and other countries in europe. Currently, with the coming of our country into aging society, BPH patients will increase, the physical and mental harm to the middle-aged and elderly people becomes more serious, and the health and economic pressure brought by BPH is more severe, so it is very important to find a method which can improve the existing medicine defects, is non-operative and can improve the prostatic hyperplasia.
Lactobacillus Plantarum N-1 can be used for preparing functional food for reducing cholesterol and promoting intestinal short chain fatty acid production, and has cholesterol reducing effect.
The invention aims to provide a known strain of lactobacillus plantarum (A)Lactobacillus Plantarum) N-1 (the following are: lactobacillus plantarum N-1) in benign prostatic hyperplasia (the following: BPH), in particular to lactobacillus plantarum N-1 used for preparing microecologics and foods for preventing and/or improving BPH.
The microecological preparation containing the lactobacillus plantarum N-1 is matched with the existing drug treatment mode of alpha-adrenergic blocker and 5 alpha reductase inhibitor to carry out combined treatment, so that the good effect on treating BPH can be achieved, and the expected effect of preventing and/or improving the BPH is remarkable especially for patients with poor effect in the existing drug treatment.
The invention develops a novel combined treatment medicine in the BPH field through the application of the lactobacillus plantarum N-1, namely a microecological preparation containing the lactobacillus plantarum N-1, which can be used for preventing and/or improving the BPH and preventing bladder outlet obstruction in the BPH early stage, and develops a novel non-medicinal non-operative auxiliary treatment mode, namely food containing the lactobacillus plantarum N-1, which can be used for preventing and/or improving the BPH and preventing bladder outlet obstruction in the BPH early stage.